PAR · ALMDT.PA
Median Technologies S.A.
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
Loading market information…
PAR · ALECR.PA · EUR
Stock price, earnings
Quote as of Jan 20, 2026, 10:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Eurofins-Cerep S.A.’s quoted price sits in the lower half of its reported 52-week range, 21.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eurofins-Cerep S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the management of chemical compounds, high-throughput screening capabilities, in vitro safety assessments, optimization of lead compounds (SAR profiling), in vitro ADME evaluations, and in vivo pharmacokinetic (PK) studies. Furthermore, it provides expert services in assay development and design. The organization, originally known as Cerep SA, officially adopted the name Eurofins Cerep SA in June 2014.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
€2.81€0.00 (0.0%)
Affluent Medical S.A.’s quoted price sits in the upper half of its reported 52-week range, 4.75% below the high.
€1.27+€0.02 (+1.59%)
Crossject S.A.’s quoted price sits in the lower half of its reported 52-week range, 52.81% below the high.
€8.90+€0.10 (+1.14%)
Sensorion S.A.’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
€0.16+€0.01 (+4.44%)
Klea Holding’s quoted price sits in the lower half of its reported 52-week range, 38.42% below the high.
€0.39-€0.00 (-0.13%)
Fermentalg’s quoted price sits in the lower half of its reported 52-week range, 39.14% below the high.
€0.55+€0.01 (+1.11%)
AB Science S.A.’s quoted price sits in the lower half of its reported 52-week range, 65.96% below the high.
€1.07+€0.03 (+2.69%)
MaaT Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 87.59% below the high.
